Orphan drugs and the NHS: should we value rarity?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 16254305.
- Also identified by PMC identifier 1273462.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The growing number and costs of drugs for rare diseases are straining healthcare budgets. Decisions on funding these treatments need to be made on a sound basis
Medical subject headings
- Orphan Drug Production
- Rare Diseases